This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Callies, F. Articles by Allolio, B. Search for Related Content PubMed PubMed Citation Articles by Callies, F. Articles by Allolio, B. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Exercise for Children Exercise and Physical Fitness Hormone Replacement Therapy

Dehydroepiandrosterone Replacement in Women with Adrenal Insufficiency: Effects on Body Composition, Serum Leptin, Bone Turnover, and Exercise Capacity

Department of Endocrinology, Medical University Hospital Wuerzburg (F.C., M.F., J.C.v.V., I.K., W.A., B.A.), 97080 Wuerzburg; Jenapharm (D.H.), 07745 Jena; and Department of Internal Medicine I, University of Heidelberg (M.J.S.), 69 M5 Heidelberg, Germany

Address all correspondence and requests for reprints to: Dr. Frank Callies, Department of Endocrinology, Medical University Hospital, Josef Schneider Strasse 2, 97080 Wuerzburg, Germany.

Studies in animals and humans using supraphysiological doses of dehydroepiandrosterone (DHEA) reported significant changes in body composition and carbohydrate metabolism. To investigate the metabolic action of a physiological DHEA replacement dose, we studied 24 women with adrenal insufficiency (AI; mean ± SD age, 42.3 ± 9.3 yr; duration of disease, 9.2 ± 8.4 yr; body mass index, 23.4 ± 4.0 kg/m²) in a double blind, placebo-controlled, randomized, cross-over design. They received 50 mg DHEA/day and placebo orally for 4 months each, with a 1 -month washout period. Measurements included fasting serum glucose, insulin, leptin, bone markers, anthropometric parameters determined by bioimpedance analysis, and exercise capacity as assessed by an incremental cycling test. DHEA did not induce any change in body mass index (placebo vs. DHEA, 23.3 ± 4.1 vs. 23.2 ± 3.9 kg/m²; P = 0.39), parameters of body composition, or exercise capacity. However, compared with placebo, DHEA replacement led to a significant decrease in serum leptin (absolute change after 4 months, DHEA vs. placebo, -5.3 ± 8.0 vs. 1.1 ± 5.7 ng/mL; P = 0.01). This is most likely the result of the DHEA-induced normalization of circulating androgens. DHEA had no effect on fasting glucose, insulin, or the glucose/insulin ratio. Compared with placebo, serum osteocalcin increased slightly, but significantly, during DHEA treatment (absolute change after 4 months DHEA vs. placebo, +1.6 ± 5.3 vs. -1.2 ± 6.2 ng/mL; P = 0.02). However, urinary cross-links excretion did not change. In conclusion, replacement of DHEA in a physiological dose in patients with pathological DHEA deficiency does not have a significant effect on carbohydrate metabolism, body composition, or exercise capacity. The biological relevance of the changes in leptin and osteocalcin levels remains to be determined.

This article has been cited by other articles:

				R. Basu, C. Dalla Man, M. Campioni, A. Basu, K. S. Nair, M. D. Jensen, S. Khosla, G. Klee, G. Toffolo, C. Cobelli, et al. Two Years of Treatment With Dehydroepiandrosterone Does Not Improve Insulin Secretion, Insulin Action, or Postprandial Glucose Turnover in Elderly Men or Women Diabetes, March 1, 2007; 56(3): 753 - 766. [Abstract] [Full Text] [PDF]

				M. E. Wierman, R. Basson, S. R. Davis, S. Khosla, K. K. Miller, W. Rosner, and N. Santoro Androgen Therapy in Women: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3697 - 3710. [Abstract] [Full Text] [PDF]

				K. K. Miller, B. M. K. Biller, C. Beauregard, J. G. Lipman, J. Jones, D. Schoenfeld, J. C. Sherman, B. Swearingen, J. Loeffler, and A. Klibanski Effects of Testosterone Replacement in Androgen-Deficient Women with Hypopituitarism: A Randomized, Double-Blind, Placebo-Controlled Study J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1683 - 1690. [Abstract] [Full Text] [PDF]

				M. C. Henson and V. D. Castracane Leptin in Pregnancy: An Update Biol Reprod, February 1, 2006; 74(2): 218 - 229. [Abstract] [Full Text] [PDF]

				W. Arlt Androgen therapy in women Eur. J. Endocrinol., January 1, 2006; 154(1): 1 - 11. [Abstract] [Full Text] [PDF]

				K. Dhatariya, M. L. Bigelow, and K. S. Nair Effect of Dehydroepiandrosterone Replacement on Insulin Sensitivity and Lipids in Hypoadrenal Women Diabetes, March 1, 2005; 54(3): 765 - 769. [Abstract] [Full Text] [PDF]

				J. J. Christiansen, C. H. Gravholt, S. Fisker, N. Moller, M. Andersen, B. Svenstrup, P. Bennett, P. Ivarsen, J. S. Christiansen, and J. O. L. Jorgensen Very short term dehydroepiandrosterone treatment in female adrenal failure: impact on carbohydrate, lipid and protein metabolism Eur. J. Endocrinol., January 1, 2005; 152(1): 77 - 85. [Abstract] [Full Text] [PDF]

				K. Lovas, G. Gebre-Medhin, T. S. Trovik, K. J. Fougner, S. Uhlving, B. G. Nedrebo, O. L. Myking, O. Kampe, and E. S. Husebye Replacement of Dehydroepiandrosterone in Adrenal Failure: No Benefit for Subjective Health Status and Sexuality in a 9-Month, Randomized, Parallel Group Clinical Trial J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1112 - 1118. [Abstract] [Full Text] [PDF]

				G. Johannsson, P. Burman, L. Wiren, B. E. Engstrom, A. G. Nilsson, M. Ottosson, B. Jonsson, B.-A. Bengtsson, and F. A. Karlsson Low Dose Dehydroepiandrosterone Affects Behavior in Hypopituitary Androgen-Deficient Women: A Placebo-Controlled Trial J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2046 - 2052. [Abstract] [Full Text] [PDF]